Ideas Weave Every Narrative with AI.
The biotech industry is obsessed with AI and high-throughput screening, hoping to find a magic wand for drug discovery. But the real bottleneck isn’t computational power—it’s our embarrassing lack of basic biological understanding. If you want to cure diseases, stop funding the shortcuts and start funding the unglamorous work of disease biology.
George Yancopoulos holds 1,000 patents. The headlines call him a genius. But that staggering number isn’t just a testament to brilliance—it’s a carefully engineered intellectual property thicket that protects Regeneron’s monopoly and keeps drug prices high. This is the uncomfortable truth behind the awe.
A landmark cancer trial has shattered the label “undruggable” — but the real story isn’t the drug. It’s that the breakthrough came from questioning a fundamental assumption the entire field had accepted as fact. Every target called “impossible” is just a question nobody’s been brave enough to answer yet.